Recombinant anti-EGFR chimeric antibody (Harbin Pharmaceutical)

重组抗EGFR人鼠嵌合单抗（哈药集团）

Report date: 2022/07/15 15:12:34

Base Information

Drug NameRecombinant anti-EGFR chimeric antibody (Harbin Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHarbin Pharmaceutical Group Holding Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHarbin Pharmaceutical Group Holding Co Ltd
Inactive CompaniesHarbin Pharmaceutical Group R&D Center
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A